Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback
4 Articles
4 Articles
A new Chinese anticancer drug, which was expected to surpass Keytruda—the world's best-selling anticancer drug manufactured by Merck (MSD)—failed to clear the approval threshold of the U.S. Food and Drug Administration (FDA). Although the drug garnered attention for demonstrating superior therapeutic efficacy compared to Keytruda in clinical trials involving Chinese patients, analysts suggest that the lack of sufficient data from patients in Wes…
Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback
Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely watched innovative drugs emerging from China, did not establish “substantial evidence of effectiveness”, said US firm Summit Therapeutics, which has the exclusive right…
Akeso's actions fell to 31.8% after Summit Therapeutics reported that the FDA did not consider that ivonescimab had demonstrated substantial evidence of efficacy.The setback occurred despite the attention the drug aroused after beating Keytruda in an advanced trial in China.
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium








